国际围产期针细胞协会建议更新美国干细胞框架,包括采用日本的风险模式、新的监管途径和允许在试验中支付病人费用。 International Perinatal Stem Cell Society recommends US stem cell framework updates, including adopting Japan's risk model, new regulatory pathway, and allowing patient payments in trials.
国际围产阶段干细胞协会呼吁更新美国干细胞监管框架. International Perinatal Stem Cell Society calls for updates to US stem cell regulatory framework. 本协会认为,目前的制度阻碍再生医学进步,提出改革建议,例如采用日本的三级风险模式,为“中等风险”产品引入新的监管途径,允许临床试验赞助者向参加某些试验的病人收取费用。 The Society argues that the current system is holding back regenerative medicine advances, proposing changes such as adopting Japan's three-tier risk model, introducing a new regulatory pathway for 'medium risk' products, and allowing clinical trial sponsors to charge patients for participation in certain trials. 学会的目标是恢复美国作为全球在再生医学和生物技术开发方面的领先者的地位,同时改善保健选择和安全标准。 The Society aims to restore the US as a global leader in regenerative medicine and biotechnology development while improving healthcare options and safety standards.